Can Fite Biopharma Ltd Tangible Net Worth Ratio
Can Fite Biopharma Ltd tangible net worth ratio. Can Fite Biopharma Ltd (CANF) has a Tangible Net Worth Ratio of 100.0% as of December 2025. This metric is calculated by deducting intangible assets (ILA0.00) from net assets (ILA5.59 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore Can Fite Biopharma Ltd (CANF) net asset momentum to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Can Fite Biopharma Ltd (2003–2025)
Tangible net worth ratio of Can Fite Biopharma Ltd from 2003 to 2025. This chart shows how Can Fite Biopharma Ltd's Tangible Net Worth Ratio has changed across 21 annual periods from 2003 to 2025. As of December 2025, the ratio stands at 100.0%, reflecting net assets of ILA5.59 Million with intangible assets of ILA0.00 ILA. Check Can Fite Biopharma Ltd (CANF) strategic investment index to assess the company's strategic physical and investment asset allocation.
Can Fite Biopharma Ltd Tangible Net Worth Ratio by Year (2003–2025)
Can Fite Biopharma Ltd tangible net worth ratio by year from 2003 to 2025. The table below presents the year-by-year Tangible Net Worth Ratio for Can Fite Biopharma Ltd from 2003 to 2025, covering 21 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see Can Fite Biopharma Ltd market capitalisation.
| Year | Tangible NW Ratio | Net Assets (ILA) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 100.0% | ILA5.59 Million | ILA0.00 | ILA9.52 Million | ▲ +0.0 pp |
| 2024 | 100.0% | ILA5.44 Million | ILA0.00 | ILA9.12 Million | ▲ +0.0 pp |
| 2023 | 100.0% | ILA6.24 Million | ILA0.00 | ILA9.99 Million | ▲ +0.0 pp |
| 2022 | 100.0% | ILA4.47 Million | ILA0.00 | ILA9.28 Million | ▲ +0.0 pp |
| 2021 | 100.0% | ILA14.38 Million | ILA0.00 | ILA20.25 Million | ▲ +0.0 pp |
| 2020 | 100.0% | ILA6.07 Million | ILA0.00 | ILA9.52 Million | ▲ +0.0 pp |
| 2019 | 100.0% | ILA2.44 Million | ILA0.00 | ILA8.17 Million | ▲ +0.0 pp |
| 2018 | 100.0% | ILA3.02 Million | ILA0.00 | ILA7.95 Million | ▲ +0.0 pp |
| 2017 | 100.0% | ILA3.05 Million | ILA0.00 | ILA7.83 Million | ▲ +0.0 pp |
| 2016 | 100.0% | ILA3.87 Million | ILA0.00 | ILA10.17 Million | ▲ +0.0 pp |
| 2015 | 100.0% | ILA10.44 Million | ILA0.00 | ILA17.60 Million | ▲ +0.0 pp |
| 2014 | 100.0% | ILA6.86 Million | ILA0.00 | ILA10.19 Million | ▲ +0.0 pp |
| 2013 | 100.0% | ILA4.46 Million | ILA0.00 | ILA6.63 Million | ▲ +0.0 pp |
| 2011 | 100.0% | ILA3.29 Million | ILA0.00 | ILA4.90 Million | ▲ +0.0 pp |
| 2010 | 100.0% | ILA13.07 Million | ILA0.00 | ILA18.55 Million | ▲ +0.0 pp |
| 2009 | 100.0% | ILA13.49 Million | ILA0.00 | ILA20.10 Million | ▲ +0.0 pp |
| 2008 | 100.0% | ILA14.79 Million | ILA0.00 | ILA21.86 Million | ▲ +0.0 pp |
| 2007 | 100.0% | ILA38.70 Million | ILA0.00 | ILA48.94 Million | ▲ +0.0 pp |
| 2006 | 100.0% | ILA38.34 Million | ILA0.00 | ILA41.76 Million | ▲ +0.0 pp |
| 2005 | 100.0% | ILA35.83 Million | ILA0.00 | ILA37.09 Million | ▲ +0.0 pp |
| 2003 | 100.0% | ILA2.07 Million | ILA0.00 | ILA2.71 Million | — |